Big Pharma Split Corp Class A (PRM) — Capital Reinvestment Ratio
Latest as of December 2023:
0.00x
Big Pharma Split Corp Class A (PRM) has a Capital Reinvestment Ratio of 0.00x as of December 2023, meaning it reinvests 0% of its operating cash flow (CA$11.86 Million) in capital expenditures (CA$3.00). See how much free cash does Big Pharma Split Corp Class A generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
CA$11.86 Million
CAD
Capital Expenditures
CA$3.00
CAD
Data as of
Dec 2023
Most recent filing
Big Pharma Split Corp Class A Capital Reinvestment Ratio (2020–2023)
This chart tracks Big Pharma Split Corp Class A's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Big Pharma Split Corp Class A (2020–2023)
Year-by-year Capital Reinvestment Ratio for Big Pharma Split Corp Class A from 2020 to 2023. For live market cap and broader valuation context, see PRM market cap.
| Year | Reinvestment Ratio | Operating CF (CAD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.00x | CA$11.86 Million | CA$3.00 | ▼ -63.3% |
| 2020 | 0.00x | CA$4.35 Million | CA$3.00 | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow